AbbVie and Alvine Pharmaceutical enter into collaboration

theflyonthewall.com

AbbVie and Alvine Pharmaceuticals announced that they have entered into a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in Phase 2 development. This collaboration builds on AbbVie's expertise and leadership in the field of gastroenterology with its on-market products to treat Crohn's disease, ulcerative colitis, and diseases associated with exocrine pancreatic insufficiency. ALV003 is an investigational oral therapy composed of two recombinant, gluten specific enzymes that degrade gluten in-vitro and in human clinical testing, and may reduce the symptoms and intestinal injury associated with celiac disease in patients attempting to adhere to a gluten-free diet

View Comments (0)